Free Trial

AbbVie (ABBV) Stock Forecast & Price Target

$173.36
-0.25 (-0.14%)
(As of 01:15 PM ET)

AbbVie - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 14 Wall Street analysts who have issued ratings for AbbVie in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 2 have given a hold rating, and 12 have given a buy rating for ABBV.

Consensus Price Target

$185.31
6.89% Upside
High Forecast$214.00
Average Forecast$185.31
Low Forecast$150.00

According to the 14 analysts' twelve-month price targets for AbbVie, the average price target is $185.31. The highest price target for ABBV is $214.00, while the lowest price target for ABBV is $150.00. The average price target represents a forecasted upside of 6.89% from the current price of $173.36.

TypeCurrent Forecast
7/24/23 to 7/23/24
1 Month Ago
6/24/23 to 6/23/24
3 Months Ago
4/25/23 to 4/24/24
1 Year Ago
7/24/22 to 7/24/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
12 Buy rating(s)
10 Buy rating(s)
7 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
8 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$185.31$179.64$177.43$163.00
Forecasted Upside6.89% Upside13.15% Upside12.83% Upside9.81% Upside
Get AbbVie Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

ABBV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ABBV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AbbVie Stock vs. The Competition

TypeAbbVieMedical CompaniesS&P 500
Consensus Rating Score
2.86
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside6.74% Upside3,007.81% Upside9.25% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/19/2024BMO Capital Markets
3 of 5 stars
 Boost TargetOutperform ➝ Outperform$180.00 ➝ $214.00+24.50%
7/11/2024Morgan Stanley
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$191.00 ➝ $196.00+15.61%
7/9/2024Cantor Fitzgerald
3 of 5 stars
L. Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.00+20.22%
7/3/2024Piper Sandler Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$190.00 ➝ $190.00+14.48%
6/5/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$185.00+14.08%
4/29/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$195.00 ➝ $187.00+16.84%
3/22/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$188.00 ➝ $190.00+6.41%
2/6/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$180.00 ➝ $195.00+13.58%
2/5/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$181.00 ➝ $189.00+12.05%
1/29/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Lugo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
12/11/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$173.00+15.89%
11/9/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$150.00+5.60%
10/20/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$157.00 ➝ $150.00+3.08%
7/12/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$170.00 ➝ $160.00+18.02%
4/28/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$200.00 ➝ $195.00+30.99%
4/5/2023Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
2/22/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Peer Perform
2/10/2023Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$157.00 ➝ $154.00+1.83%
2/10/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Market Perform$135.00 ➝ $153.00+2.89%
2/10/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Market Perform$135.00 ➝ $153.00+2.89%
11/8/2022Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$155.00 ➝ $140.00-7.32%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 01:34 PM ET.

ABBV Forecast - Frequently Asked Questions

What is AbbVie's forecast for 2024?

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for AbbVie is $185.31, with a high forecast of $214.00 and a low forecast of $150.00.

Should I buy or sell AbbVie stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ABBV shares.

Does AbbVie's stock price have much upside?

According to analysts, AbbVie's stock has a predicted upside of 13.77% based on their 12-month stock forecasts.

Has AbbVie been upgraded by Wall Street analysts recently?

Over the previous 90 days, AbbVie's stock had 1 upgrade by analysts.

What analysts cover AbbVie?

AbbVie has been rated by research analysts at Barclays, BMO Capital Markets, Cantor Fitzgerald, HSBC, Morgan Stanley, Piper Sandler, and Piper Sandler Companies in the past 90 days.

Do Wall Street analysts like AbbVie more than its competitors?

Analysts like AbbVie more than other "medical" companies. The consensus rating score for AbbVie is 2.86 while the average consensus rating score for "medical" companies is 2.72. Learn more on how ABBV compares to other companies.


This page (NYSE:ABBV) was last updated on 7/23/2024 by MarketBeat.com Staff

From Our Partners